MEDEVA SEMPREX-D (Semprex-D 8 mg-60 mg)
Generic Name: acrivastine/pseudoephedrine
Pill imprint MEDEVA SEMPREX-D has been identified as Semprex-D 8 mg-60 mg.
Semprex-D is used in the treatment of allergic rhinitis; nasal congestion and belongs to the drug class upper respiratory combinations. There is no proven risk in humans during pregnancy. Semprex-D 8 mg-60 mg is not a controlled substance under the Controlled Substance Act (CSA).
- Generic Name:
- acrivastine/pseudoephedrine
- Imprint:
- MEDEVA SEMPREX-D
- Strength:
- 8 mg-60 mg
- Color:
- Green & White
- Shape:
- Capsule-shape
- Availability:
- Prescription only
- Drug Class:
- Upper respiratory combinations
- Pregnancy Category:
- B - No proven risk in humans
- CSA Schedule:
- Not a controlled drug
- Manufacturer:
- Celltech Pharmaceuticals Inc.
- National Drug Code (NDC):
- 53014-0404
- Inactive Ingredients:
- lactose
magnesium stearate
sodium starch glycolate
gelatin
D&C Yellow No. 10
FD&C Green No. 3
titanium dioxide
More about Semprex-D (acrivastine / pseudoephedrine)
Consumer resources
Professional resources
Related treatment guides
Disclaimer:
Every effort has been made to ensure that the information provided is accurate, up-to-date, and complete, but no guarantee is made to that effect. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.
Copyright 2016 Drugs.com, National Library of Medicine, Truven Health Analytics and Cerner Multum, Inc. All Rights Reserved.
